Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants.
Poh XY, Mah SYY, Yeoh AYY, Chavatte JM, Lim DRX, Tan CCY, Tang HL, Gandhi M, Rahman N, Rao S, Chia PY, Sadarangani SP, Chin YQ, Ng LFP, Renia L, Lin RTP, Lye DC, Wang LF, Tan CW, Young BE. Poh XY, et al. Hum Vaccin Immunother. 2026 Dec;22(1):2638022. doi: 10.1080/21645515.2026.2638022. Epub 2026 May 5. Hum Vaccin Immunother. 2026. PMID: 42083894 Free PMC article. Clinical Trial.
Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial.
Sullivan SG, Poh XY, Sanchez-Ovando S, Hadiprodjo AJ, Carolan L, Chin YQ, Rao S, Sutjipto S, Lim J, Anthony D, Sadarangani SP, Barr IG, Young B, Fox A. Sullivan SG, et al. Among authors: poh xy. Lancet Infect Dis. 2026 Apr 2:S1473-3099(26)00062-9. doi: 10.1016/S1473-3099(26)00062-9. Online ahead of print. Lancet Infect Dis. 2026. PMID: 41936374 Free article.
MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival.
Poh XY, Loh FK, Bai C, Chong HT, Teo WK, Wong YH, Hong JM, Miow QH, Thong PM, Vilaysane B, Hu TH, Chhabra S, Wang Y, Tiong SC, Fong SM, Kamihigashi M, Rajarethinam R, Looi WD, Cheow ESH, Bonney GK, Pakkiri LS, Drum CL, Peng YF, Lee M, Tan CL, Ding CSL, Lim TCC, Yeo TW, Tay JK, Vallejo AF, Ong CWM. Poh XY, et al. J Neuroinflammation. 2025 Oct 11;22(1):230. doi: 10.1186/s12974-025-03548-7. J Neuroinflammation. 2025. PMID: 41076519 Free PMC article.
Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection.
Ponce LJ, Wang Y, Singh A, Chua HK, Chen M, Hor PX, Loh CY, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Lim C, Teo J, Goh YS, Ejima K; on behalf of the NCID Study Group; on behalf of the COVID‐19 Cohort Study Group. Ponce LJ, et al. Among authors: poh xy. J Med Virol. 2025 Aug;97(8):e70521. doi: 10.1002/jmv.70521. J Med Virol. 2025. PMID: 40767533 Free PMC article.
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Poh XY, Torres-Ruesta A, Yoong T, Wong N, Tan CW, Rouers A, Chavatte JM, Goh YS, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Neo V, Kam IKJ, Huang Y, Hor PX, Loh CY; PRIBIVAC study group; Yeoh AY, Lim DRX, Chia W, Ren EC, Lin RTP, Fong SW, Renia L, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5. Vaccine. 2024. PMID: 39241318 Free article. Clinical Trial.
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
Poh XY, Lee IR, Tan CW, Chavatte JM, Fong SW, Goh YS, Rouers A, Wong N, Torres-Ruesta A, Mah SYY, Yeoh AYY, Gandhi M, Rahman N, Chin YQ, Lim JJ, Yoong TJK, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Lim DRX, Chia W, Renia L, Ren EC, Lin RTP, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. EBioMedicine. 2024 Sep;107:105275. doi: 10.1016/j.ebiom.2024.105275. Epub 2024 Aug 12. EBioMedicine. 2024. PMID: 39137572 Free PMC article. Clinical Trial.
Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1).
Goh YS, Fong SW, Hor PX, Loh CY, Tay MZ, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Lee IR, Rao S, Chia PY; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L. Goh YS, et al. Among authors: poh xy. Int J Infect Dis. 2024 Sep;146:107147. doi: 10.1016/j.ijid.2024.107147. Epub 2024 Jun 28. Int J Infect Dis. 2024. PMID: 38945433 Free article.
Variant-Specific IgA Protects Against Omicron Infection.
Goh YS, Fong SW, Hor PX, Loh CY, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES, Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L; NCID Study Group; COVID-19 Cohort Study Group. Goh YS, et al. Among authors: poh xy. J Infect Dis. 2024 Aug 16;230(2):e287-e291. doi: 10.1093/infdis/jiad525. J Infect Dis. 2024. PMID: 37996071 Free PMC article. Clinical Trial.
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant.
Tay MZ, Goh YS, Fong SW, Chang ZW, Rouers A, Wong N, Torres-Ruesta A, Huang Y, Selvam SK, Hor PX, Loh CY, Wang B, Mohd Salleh SN, Ngoh EZX, Lee RTC, Neo V, Kam IKJ, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J; NCID Study Group; PRIBIVAC Cohort Study Group; Maurer-Stroh S, Wang CI, Leo YS, Lin RTP, Lye DC, Young BE, Ng LFP, Renia L. Tay MZ, et al. Among authors: poh xy. Lancet Reg Health West Pac. 2023 Apr;33:100732. doi: 10.1016/j.lanwpc.2023.100732. Epub 2023 Mar 7. Lancet Reg Health West Pac. 2023. PMID: 37125085 Free PMC article. No abstract available.
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.
Rouers A, Wong N, Goh YS, Torres-Ruesta A, Tay MZ, Chang ZW, Fong SW, Neo V, Kam IKJ, Yeo NK, Huang Y, Loh CY, Hor PX, Wong JXE, Tan YJ; COVID-19 Study Group; Macary PA, Qian X, Bei W, Ngoh EZX, Salleh SNM, Wang CI, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Lim C, Teo J, Ren EC, Lye DC, Young BE, Ng LFP, Renia L. Rouers A, et al. Among authors: poh xy. J Med Virol. 2023 Jan;95(1):e28258. doi: 10.1002/jmv.28258. Epub 2022 Nov 16. J Med Virol. 2023. PMID: 36305052 Free PMC article.
17 results